Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs

Introduction: Somatostatin analogs (SSAs) are used as part of standard treatment for advanced neuroendocrine tumors (NETs). The mechanisms behind the antiproliferative action of SSAs remain largely unknown, but a connection with the mammalian target of rapamycin (mTOR) signaling pathway has been sug...

Full description

Bibliographic Details
Main Author: Fernandes, Isabel (author)
Other Authors: Pacheco, Teresa R. (author), Costa, Adília (author), Santos, Ana C. (author), Fernandes, Ana R. (author), Santos, Mara (author), Oliveira, António G. (author), Casimiro, Sandra (author), Quintela, António (author), Fernandes, Afonso (author), Ramos, Madalena (author), Costa, Luís (author)
Format: article
Language:eng
Published: 2017
Subjects:
MTOR pathway
Neuroendocrine tumor
Somatostatin analogs
Oncology
Pharmacology (medical)
Online Access:https://doi.org/10.2147/OTT.S36330
Country:Portugal
Oai:oai:run.unl.pt:10362/24690

Internet

https://doi.org/10.2147/OTT.S36330

Similar Items